Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,726,192

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Ritujay Ghosh headshot

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.

Eli Lilly and Company, PVH, Alphabet, Starbucks and Ford Motor highlighted as Zacks Bull and Bear of the Day

Eli Lilly and Company, PVH, Alphabet, Starbucks and Ford Motor highlighted as Zacks Bull and Bear of the Day

Tracey Ryniec headshot

Bull of the Day: Eli Lilly (LLY)

Double digit earnings growth expected in 2020 and it pays a dividend too.

Sheraz Mian headshot

Top Stock Research Reports for Cisco, Abbott, NextEra & Others

Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

Merck (MRK) beats estimates for earnings as well as for sales in first-quarter 2019. The company lowers its sales and earnings guidance to include impact of COVID-19. Shares down.

Kinjel Shah headshot

Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS

Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.

Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y

Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.

Company News for Apr 24, 2020

Companies In The News Are: LLY, SAVA, FLR, LYTS

Will Eli Lilly and Company Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Eli Lilly and Company

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN

Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Mark Vickery headshot

Jobless Claims Still High but Coming Down, Plus More Q1 Results

4.427 million new jobless claims were made in the past week, bringing the total of the past 5 weeks of new claims data to north of 26 million workers in the U.S.

Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits

Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.

Economic Data Deluge

Economic Data Deluge

Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of 12.90% and 6.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke

The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

Sanofi (SNY) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.

Is a Surprise Coming for Lilly (LLY) This Earnings Season?

Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?

Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.

The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy

The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy

Nalak Das headshot

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.